GlyB4 Fusion Protein for CNS Penetration and NRG Signal Blocking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for neurodegenerative diseases and central nervous system disorders, such as Alzheimer's and ALS, do not effectively address inflammation and plaque formation, and most protein drugs fail to penetrate the central nervous system.

Innovation Solution

Administration of the GlyB4 fusion protein, which penetrates the central nervous system, acts as a targeted antagonist to block endogenous neuregulin signaling, reducing inflammation and preventing plaque formation by blocking NRG receptors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If protein drugs are administered to treat neurodegenerative diseases, then therapeutic effects are achieved, but the drugs fail to penetrate the central nervous system

Engineering Contradiction:

Improvetherapeutic effectVSAvoidinability to penetrate CNS

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses a fusion protein design where the NRG1 extracellular domain is fused to the erbB4 extracellular domain. The NRG1 domain acts as an intermediary that binds to heparin sulfate proteoglycans on the surface of CNS cells, facilitating penetration into the central nervous system, while the erbB4 domain provides the therapeutic blocking function against NRG signaling.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If existing treatments are used for neurodegenerative diseases, then disease progression is addressed, but inflammation and plaque formation are not effectively treated

Engineering Contradiction:

Improvedisease progression controlVSAvoidinflammation and plaque formation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The fusion protein exerts preliminary anti-action by blocking NRG signaling pathways before they can trigger inflammatory responses and plaque formation. By preventing the activation of erbB4 receptors by endogenous NRG1, the treatment proactively inhibits the signaling cascades that lead to microglial activation, inflammation, and amyloid plaque formation.

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

GlyB4 fusion protein effectively reduces activated microglia, Aβ plaques, and microglial activation, slowing disease progression and rescuing motor neurons in animal models of Alzheimer's and ALS.

Implementation Method 1

The neuregulins (NRGs) are a family of heparin-binding growth and differentiation factors

Methodology Applied

Scientific EffectHeparin binding: Absorption (physical)

Implementation Method 2

NRGs released from motor nerve endings at neuromuscular synapses activate members of the epidermal growth factor (EGF) family of tyrosine kinase receptors erbB2, erbB3 and erbB4 in the postsynaptic muscle membrane

Methodology Applied

Scientific EffectReceptor binding and blocking: Absorption (physical)

Data Source

PatentUS12466865B2Method and kit for treating a neurodegenerative disease

Publication Date: 2025.11.11 THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

AI summary

A method and kit for treating a neurodegenerative disease or central nervous system disorder in a subject using a GlyB4 fusion protein is provided, as is a kit containing the same.